Join

Compare · ARPO vs TRIL

ARPO vs TRIL

Side-by-side comparison of Aerpio Pharmaceuticals, Inc. (ARPO) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARPO and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
  • TRIL is the larger of the two at $1.94B, about 4.6x ARPO ($425.1M).
  • TRIL has more recent analyst coverage (5 ratings vs 1 for ARPO).
MetricARPOTRIL
Company
Aerpio Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
Price
$2.19-1.57%
$19.30-3.45%
Market cap
$425.1M
$1.94B
1M return
-
-3.79%
1Y return
-
-5.02%
Industry
Major Pharmaceuticals
Major Pharmaceuticals
Exchange
NASDAQ
NASDAQ
IPO
n/a
n/a
News (4w)
0
0
Recent ratings
1
5
ARPO

Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.

TRIL

Trillium Therapeutics Inc.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.